Group 1 - The company announced that its first extraordinary general meeting of shareholders for 2025 will be held on September 8, 2025 [2] - The meeting will review and approve several proposals, including the proposal to change the purpose of part of the repurchased shares and to cancel them [2]

Group 1 - The company announced the cancellation of part of the repurchased shares and a capital reduction on September 8, 2025 [1] - The board meetings held on August 21, 2025, and the extraordinary shareholders' meeting on September 8, 2025, approved the change in the purpose of the repurchased shares [1] - The repurchased shares, originally intended for employee stock incentive plans, will now be used for cancellation and reduction of registered capital [1] Group 2 - A total of 2,022,344 shares will be canceled, reducing the total share capital from 545,464,520 shares to 543,442,176 shares [1] - The registered capital will decrease from RMB 545,464,520 to RMB 543,442,176 following the cancellation [1] - Creditors have 45 days from the announcement date to claim debts or request guarantees due to the capital reduction [1]

1、本次股东会召开期间没有增加、否决或变更议案情况发生； 2、本次股东会不涉及变更前次股东会决议； 股票代码：300363 股票简称：博腾股份 公告编号：2025-048 号 重庆博腾制药科技股份有限公司 2025 年第一次临时股东会决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 同意 240,358,789 股，占参加本次股东会的股东所持有表决权股份总数 99.9297%；反对 127,300 股，占参加本次股东会的股东所持有表决权股份总数 0.0529%；弃权 41,910 股，占参加本次股东会的股东所持有表决权股份总数 0.0174%。 3、本次股东会采取现场投票与网络投票相结合的方式召开。 一、会议召开和出席情况 重庆博腾制药科技股份有限公司（以下简称"公司"）2025 年第一次临时 股东会于 2025 年 9 月 8 日（星期一）14:30 在重庆市北碚区云图路 7 号公司研发 大楼 2-2 会议室以现场投票与网络投票相结合的方式召开。本次股东会由公司董 事会召集，董事长居年丰因其他公务安排无法履行本次股东会主持人职务，经公 司半 ...

北京市万商天勤律师事务所 关于重庆博腾制药科技股份有限公司 2025 年第一次临时股东会的 法律意见书 1 北京市万商天勤律师事务所关于 重庆博腾制药科技股份有限公司 2025 年第一次临时股东会的 法律意见书 致：重庆博腾制药科技股份有限公司 北京市万商天勤律师事务所（以下简称"本所"）接受重庆博腾制药科技股 份有限公司（以下简称"公司"）的委托，指派律师出席了公司召开的 2025 年 第一次临时股东会。根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和规范性 文件以及《重庆博腾制药科技股份有限公司章程》（以下简称"《公司章程》"） 的要求，就公司 2025 年第一次临时股东会（以下简称"本次临时股东会"）的 相关事宜出具本法律意见书。 公司已向本所律师提供了本所律师认为出具本法律意见书必要的文件资料， 本所律师对该等文件和资料进行了核查、验证，并据此出具法律意见。 本所律师仅就本次临时股东会的召集、召开程序、出席会议人员资格、召 集人资格及会议表决程序、表决结果是否符合《公司法》、《股东会规则》以及 《公司章程》发表意见。 本所律师同意 ...

重庆博腾制药科技股份有限公司（以下简称"公司"）分别于 2025 年 8 月 21 日召开第六届董事会第三次会议和第六届监事会第二次会议、于 2025 年 9 月 8 日召开 2025 年第一次临时股东会，审议通过《关于变更部分回购股份用途并 注销的议案》，同意对公司于 2022 年 8 月 4 日召开的第五届董事会第六次临时 会议审议通过的《关于以集中竞价交易方式回购股份的议案》的回购股份（以下 简称"2022 年回购"）用途进行变更，由"用于实施股权激励或员工持股计划" 变更为"用于注销并减少公司注册资本"，并对 2022 年回购的全部股份，共计 2,022,344 股，予以注销。具体情况详见公司分别于 2025 年 8 月 23 日在巨潮资 讯网（www.cninfo.com.cn）披露的《关于变更部分回购股份用途并注销的公告》 （公告编号：2025-045号）、于2025 年9 月8日在巨潮资讯网（www.cninfo.com.cn） 披露的《2025 年第一次临时股东会决议公告》（公告编号：2025-048 号）。 上述注销实施完毕后，公司总股本将由 545,464,520 股变更为 543,442 ...

Core Viewpoint - The medical services sector experienced a significant increase of 3.79% on September 5, with Zhaoyan New Drug leading the gains [1] Market Performance - The Shanghai Composite Index closed at 3812.51, up 1.24% - The Shenzhen Component Index closed at 12590.56, up 3.89% [1] Individual Stock Performance - Zhaoyan New Drug (603127) closed at 34.01, up 9.99% with a trading volume of 578,000 shares and a transaction value of 1.905 billion yuan - Tiger Medical (300347) closed at 66.58, up 6.66% with a trading volume of 146,300 shares and a transaction value of 950 million yuan - Kailaiying (002821) closed at 108.27, up 6.44% with a trading volume of 114,500 shares and a transaction value of 1.213 billion yuan - Posens (301257) closed at 49.20, up 5.81% with a trading volume of 84,700 shares and a transaction value of 407 million yuan - Kanglong Chemical (300759) closed at 31.30, up 5.56% with a trading volume of 615,400 shares and a transaction value of 1.887 billion yuan - WuXi AppTec (603259) closed at 107.40, up 5.36% with a trading volume of 802,300 shares and a transaction value of 8.39 billion yuan - Jiuzhou Pharmaceutical (603456) closed at 19.15, up 5.22% with a trading volume of 441,000 shares and a transaction value of 827 million yuan - ST Biological (000504) closed at 9.68, up 4.99% with a trading volume of 49,800 shares and a transaction value of 4.749 million yuan - Nossger (301333) closed at 58.02, up 4.94% with a trading volume of 56,100 shares and a transaction value of 32.2 million yuan - Boteng Co., Ltd. (300363) closed at 25.90, up 4.73% with a trading volume of 396,800 shares and a transaction value of 1.011 billion yuan [1] Capital Flow - The medical services sector saw a net inflow of 423 million yuan from institutional investors, while retail investors experienced a net outflow of 58.5864 million yuan [1]

Group 1 - The CRO (Contract Research Organization) concept stocks in the A-share market have shown strong performance, with notable gains in several companies [1] - Zhaoyan New Drug approached the daily limit increase with a rise of 9.12%, while other companies like Kailaiying, Nossger, and Kanglong Chemical also saw increases exceeding 5% [1][2] - The total market capitalization of Zhaoyan New Drug is 25.3 billion, and it has achieved a year-to-date increase of 103.06% [2] Group 2 - Kailaiying's stock rose by 5.48%, with a total market capitalization of 38.7 billion and a year-to-date increase of 42.84% [2] - Nossger and Kanglong Chemical experienced increases of 5.44% and 5.19%, respectively, with market capitalizations of 5.631 billion and 55.5 billion [2] - Other companies such as Sunshine Nuohuo and Boteng also reported gains of over 5%, with year-to-date increases of 109.05% and 64.55% respectively [2]

Market Overview - On September 4, the medical services sector declined by 4.28%, with Bid Pharma leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the medical services sector included: - Zihua Pharmaceutical (600721) with a closing price of 11.07, up 6.24% [1] - Innovation Medical (002173) with a closing price of 24.99, up 5.31% [1] - Wisdom Pharmaceutical (300149) with a closing price of 13.17, up 4.36% [1] - Major decliners included: - Bid Pharma (688073) with a closing price of 62.65, down 9.44% [2] - WuXi AppTec (603259) with a closing price of 101.94, down 8.06% [2] - Zhaoyan New Drug (603127) with a closing price of 30.92, down 7.48% [2] Capital Flow - The medical services sector experienced a net outflow of 1 billion yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2][3] - Key stocks with significant capital flow included: - Innovation Medical (002173) with a net inflow of 136 million yuan from institutional investors [3] - Wisdom Pharmaceutical (300149) with a net inflow of 79 million yuan from institutional investors [3] - Meinian Health (002044) with a net inflow of 64 million yuan from institutional investors [3]

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industries and the 14th Pharmaceutical CEO Forum, highlighting the focus on innovation and global expansion of Chinese pharmaceutical companies [1]. Summary by Sections Event Overview - The event will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai, featuring nearly a hundred executives from listed companies, including chairpersons, CEOs, and industry leaders [4]. Morning Sessions - The morning session on September 4 will include a keynote speech and several roundtable discussions focusing on topics such as the global expansion of Chinese pharmaceutical companies and the search for the next billion-dollar drug [4][5]. - Notable discussions will include: - "From Local Innovation to Global Leadership: The Era of Chinese Pharmaceutical Companies Going Abroad" [4]. - "The Birth of Big Drugs is the Future of Pharmaceuticals: Finding the Next Billion-Dollar Bomb" [4]. Afternoon Sessions - The afternoon will feature discussions on future disease areas and technologies worth exploring for pharmaceutical assets going abroad, as well as the new cycle of Chinese innovative drugs under global competition [5][6]. - Additional topics will cover advancements in drug development platforms and the emerging field of brain-machine interfaces [6]. TMT Forum - The TMT (Technology, Media, and Telecommunications) forum will also take place, discussing AI's impact on various industries, including gaming and healthcare [7][8]. - Key topics will include AI innovations in mobile internet ecosystems and the future of AI in healthcare [7]. Pharmaceutical Sub-Forum - The pharmaceutical sub-forum will address topics such as ADC technology exploration, probiotic delivery systems, and the future development paths of dual antibodies and XDC [8]. - Discussions will also focus on the integration of medical insurance and the innovative practices in building a multi-level medical security system in China [8].

Group 1 - The company, Boteng Co., Ltd. (stock code: 300363), reported that as of August 29, 2025, the total number of shareholders (including both ordinary accounts and margin trading accounts) is 52,666 [1]